莱盟健康

Laboratory for Advanced Medicine & Health

Laboratory for Advanced Medicine & Health Group (LAMH) is an AI-driven cancer screening and early diagnosis innovation company founded by international business leaders, top scientists and authoritative doctors with the concept of "making cancer screening more accurate, earlier and easier". LAMH was founded by international business leaders, top scientists and authoritative doctors with the concept of "making cancer screening more accurate, earlier and easier", and has raised over RMB 1 billion since its inception. As a global leader in early screening and diagnosis of cancer, LAMH has collaborated with many top cancer centers, universities and their affiliated hospitals, published relevant research results in top international journals such as Nature, Science, Cell and its sub-journals, PNAS, and established a full product pipeline for early screening and diagnosis of liver cancer, intestinal cancer, lung cancer and pan-cancer. LAMH is committed to providing a full lifecycle service system with the help of AI-driven technology, combined with genomics and clinical medicine theories.

LAMH is headquartered in Beijing Economic and Technological Development Zone (BEDZ), with PCR and NGS compliant laboratories in Guangzhou Bio-Island and BEDZ, and an IVD GMP factory in Guangzhou Science City that has passed the NMPA system assessment.

Mission

Making cancer screening

more accurate earlier and easier

Vision

Technology-driven global leader

in early cancer screening

Values

Result-driven, customer-centric

striver-oriented

Core Technology

Technology-Driven Global Leader In Early Screening
And Diagnosis Of Cancer

The world's first large scale liver cancer early screening research results based on cfDNA methylation technology, pioneering the use of cfDNA methylation for early cancer screening.

LAMH research results show that methylation markers can be used effectively in the diagnosis and prognosis of breast, colorectal, liver and lung cancers.

CHALM-cell heterogeneity-adjusted methylation quantitative analysis method.

Research published in the Journal of the American Association for the Study of Liver Cancer has shown that the LAMH HelioLiver Test, a liver cancer early screening product, can accurately detect early stage liver cancer.

Product

早诊精准解决方案

IvyGene® Liver

Hepatocellular carcinoma gene
methylation test

View Details

IvyGene®Liver Plus

Hepatocellular carcinoma gene
methylation test

View Details

lvyGene® PLUS

Early and accurate cancer screening

View Details

Core Team

Zeyue Zhang

Chairman / CEO

Zeyue Zhang

Chairman / CEO

Mr. Zeyue Zhang has a rich background in Business, clinical medicine and biotechnology in the gene industry; He has management experience in start-up companies, multinational enterprises, well-known private enterprises and state-owned enterprises. He has worked in well-known domestic gene companies such as BGI, BoA, Roche and Novartis, as well as the sales department of well-known multinational pharmaceutical companies.

Bachelor of Medicine, Southern Medical University;
Executive Master of Business Administration (EMBA) from China Europe International Business School (CEIBS).

Shu Li

Founder / Co-Chairman

Shu Li

Founder / Co-Chairman

Dr. Shu Li is a successful entrepreneur in the biomedical field. He served as senior vice president of Conexant Systems, vice president and general manager of Honeywell Commercial Spare Parts, and held senior management positions in Motorola and Intel. Dr. Li Shu is a member of the Advisory Board of the University of California, Irvine (Business School), and has also served as a faculty member at the University of Arizona. He holds 6 US and international patents.

Bachelor of Automatic Control from Huazhong University of Science and Technology;
Degree in Electrical Engineering from the University of Illinois at Urbana-Champaign;
PhD in Applied Science from Harvard University.

Company History

2010

World's First Methylation Technology Company

LAMH Receives UCSD's World's First Methylation Cancer Screening Technology

2015

LAMH Was Officially Established

2016

Awarded PCT patent

Including solid tumors, colon cancer, lung cancer, leukemia, breast and ovarian cancer, liver cancer methylation markers and their uses

2017

Awarded China Patent

Methylation for diagnosis of stem cell carcinoma and lung cancer methylation markers, methylation markers for cancer diagnosis methylation markers for cancer diagnosis

2018

Liver Cancer NMPA Registry Check Completed

The world's first company to pass the IVD registration test for liver cancer methylation detection in China

2019

First to initiate Chinese NMPA liver cancer clinical trial

Received a major project from the Ministry of Science and Technology of China

Jointly awarded a major project by the Ministry of Science and Technology with the National Cancer Center NCC

2020

Completion of NMPA China liver cancer clinical trial

Release of NMPA clinical trial data for liver cancer

2021

Passed PCR laboratory acceptance

Multi-omics for early screening of bowel cancer Blood product sizing

2021

Commercialization of liver cancer products in China

Officially launched the LDT test for liver cancer in China Scale up commercialization

Pan-cancer early screening multi-omics Blood product marker screening

Early screening LDT product launch for five cancer types

2022

LAMH MR Liver Cancer Recurrence Surveillance Program Launched at Lyman Health

History

全球最早甲基化技术公司

莱盟健康LAMH通过UCSD全球首创甲基化癌症筛查技术

莱盟健康LAMH正式成立

获授PCT专利

包括实体肿瘤、结肠癌、肺癌、白血病、乳腺癌和卵巢癌、肝癌甲基化标记物及其用途

获授中国专利

用于诊断干细胞癌和肺癌甲基化的甲基化标记物、用于癌症诊断的甲基化标记物

肝癌NMPA注册检完成

全球首家通过中国肝癌甲基化检测IVD
注册检的企业

首家启动中国NMPA肝癌临床试验

获得中国科技部重大专项

与国家癌症中心NCC共同获得科技部重大
专项

完成NMPA中国肝癌临床试验

发布肝癌NMPA临床试验数据

通过PCR实验室验收

肠癌早筛多组学血液产品定型

中国肝癌产品商业化

正式启动中国肝癌LDT检测产品规模化
商业化

泛癌种早筛多组学血液产品marker筛选

五癌种早筛LDT产品启动

莱盟健康LAMH MR肝癌复发监测项目启动

Latest News

LAMH and Baidu Health enter into a strategic cooperation: promoting early screening and diagnosis of cancer for all

LAMH was awarded the “Zhongguancun High-tech Enterprise” certification, and its technological innovation capability was recognized again

Cutting-edge cooperation

Stanford Medicine

Johns Hopkins

Harvard Medical School

Cleveland Clinic

UCI Rvine

Uc San Diego

Purdue University

University Of Arizona

U Health

Moffitt Cancer Center

Ochsner Health

Cedars Sinai

Listed in no particular order

《Nature Materials》

The researchers performed ctDNA methylation model analysis on 1098 liver cancer patients and 835 normal human samples, and established a comprehensive methylation diagnostic model (AUC: 0.969) and a comprehensive prognostic model with high sensitivity and specificity by targeted methylation sequencing method to screen 10 and 8 methylation sites for real-time tumor load detection, treatment response, recurrence monitoring and prognostic assessment. The comprehensive diagnostic model has higher sensitivity and specificity in stage I, II, and III tumors compared to the AFP assay, which does not vary much in other stages of liver cancer except for stage III and IV.

《PNAS》

Using NGS technology, the study conducted artificial intelligence training on methylation data of 3,771 samples from three databases of TCGA and Chinese clinical samples to screen specific methylation models for four common cancers (breast cancer, colorectal cancer, liver cancer, and lung cancer). The validation results showed that the methylation models achieved over 95% accuracy in detecting the four cancers in the Chinese population.

《Nature Communications》

Current methods for quantitative methylation analysis do not take into account the heterogeneity of cells at the time of sequencing, which can lead to poor correlation between methylation analysis results and gene expression data. the CHALM algorithm helps us to better reveal the function of DNA methylation and its association with gene expression.

《Nature Materials》

HelioLiver Test, a blood test combining cfDNA methylation patterns with tumor protein markers for analysis, achieved a sensitivity of 85% for detection of liver cancer and 76% for early stage (AJCC stages I and II), as well as a specificity of 91% in a double-blind, multicenter clinical validation study collecting 122 patients with liver cancer and 125 patients with cirrhosis, with significantly better detection performance than AFP and GALAD models.